Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 6—June 2021
Research

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

Matt WassermanComments to Author , Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, and Stephen Pelton
Author affiliations: Pfizer Inc., New York, New York, USA (M. Wasserman, E. Chilson, V. Snow, R. Farkouh); Evidera Market Access Ltd, London, UK (R. Chapman, K. Sutton, D. Dillon-Murphy, S. Patel); Boston University School of Medicine, Boston, Massachusetts, USA (R. Lapidot, S. Pelton)

Main Article

Table 2

Cases of invasive pneumococcal disease averted by PCV13, United States, 1997–2019*

Year No. observed
No. expected
Cumulative cases averted
Difference in non-PCV13 serotype cases†
All PCV13 serotypes Non-PCV13 serotypes All PCV13 serotypes Non-PCV13 serotypes All PCV13 serotypes
1997 15,543 14,439 1,104 15,543 14,439 1,104 NA NA NA
1998 18,136 16,848 1,288 18,136 16,848 1,288 NA NA NA
1999 17,785 16,839 945 17,785 16,839 945 NA NA NA
2000 15,306 13,808 1,498 17,364 16,178 1,186 2,057 2,369 −312
2001 7,887 6,561 1,325 17,689 16,481 1,208 11,860 12,289 −429
2002 4,596 3,109 1,487 17,899 16,677 1,223 25,164 25,857 −693
2003 4,577 2,743 1,834 17,874 16,653 1,221 38,460 39,767 −1,307
2004 4,192 2,374 1,818 18,013 16,783 1,230 52,281 54,175 −1,894
2005 4,336 2,589 1,747 18,101 16,864 1,236 66,046 68,450 −2,405
2006 4,219 2,592 1,627 18,130 16,891 1,238 79,956 82,750 −2,793
2007 4,537 3,019 1,518 18,372 17,118 1,255 93,792 96,848 −3,057
2008 4,221 2,635 1,585 18,562 17,294 1,268 108,133 111,507 −3,374
2009 4,449 3,037 1,412 18,358 17,104 1,254 122,043 125,575 −3,532
2010 4,014 2,626 1,388 18,074 16,839 1,235 136,103 139,788 −3,685
2011 2,515 805 1,710 18,085 16,850 1,235 151,674 155,833 −4,160
2012 1,870 400 1,470 18,009 16,779 1,230 167,813 172,213 −4,400
2013 1,988 397 1,591 17,916 16,692 1,224 183,741 188,508 −4,766
2014 1,790 397 1,392 17,963 16,736 1,227 199,914 204,846 −4,932
2015 1,856 398 1,457 18,053 16,820 1,233 216,112 221,268 −5,156
2016 906 398 507 18,068 16,834 1,234 233,275 237,703 −4,429
2017 1,391 398 993 17,934 16,709 1,225 249,818 254,015 −4,197
2018 1,382 396 986 17,752 16,539 1,213 266,188 270,158 −3,970
2019 1,382 396 986 17,752 16,539 1,213 282,558 286,302 −3,744

*Values are rounded to the nearest whole numbers. NA, not applicable; PCV13, 13-valent pneumococcal conjugate vaccine. 
†Negative values indicate greater number observed than would be expected.

Main Article

Page created: April 15, 2021
Page updated: April 29, 2021
Page reviewed: April 29, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external